Ekso Bionics designs, develops, and sells robotic exoskeletons — wearable powered devices that assist limb movement. The company focuses on two healthcare markets: Enterprise Health, where hospitals and clinics use Ekso's devices to rehabilitate patients recovering from strokes, spinal cord injuries, traumatic brain injuries, and MS; and Personal Health, where individuals with spinal cord injuries use Ekso's devices for at-home and community mobility. Core products are the EksoNR (clinical rehab) and Ekso Indego family (both a therapy version for clinics and a personal version for individuals). Enterprise Health represents roughly 75-80% of revenue, with Personal Health growing to around 25%. Ekso sells enterprise devices directly to rehabilitation hospitals and IDNs in the Americas, and through a mix of direct and distributor channels elsewhere. Personal devices are sold through DME and O&P distributors, who manage Medicare reimbursement on behalf of patients. Revenue comes primarily from outright device sales, supplemented by recurring service and maintenance contracts (EksoCare). Ekso's near-term growth is centered on scaling Personal Health through the Medicare reimbursement pathway unlocked by a 2024 CMS pricing determination, building a network of DME and O&P distribution partners to reach eligible patients. Ekso is also developing an AI foundation model for human motion using its database of roughly 350,000 patient sessions, and has new products in development including the Ekso Nomad powered orthosis targeted for launch in late 2026.